Welsh Government has approved new advice from the All Wales Medicines Strategy Group (AWMSG) for two medicines.
- fampridine (Fampyra®) was recommended to improve walking in adults (18 years and over) with multiple sclerosis related walking disability.
- glycerol phenylbutyrate (Ravicti®) was recommended to treat six known ‘urea cycle disorders’ in adults and children. Ravicti® contains the active substance ‘glycerol phenylbutyrate.
AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.